|
1) Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol. 2000; 164: 2-14
|
|
|
|
2) Forsayeth JR, Eberling JL, Sanftner LM, et al. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther. 2006; 14: 571-7
|
|
|
|
|
|
3) Sanchez-Pernaute R, Harvey-White J, Cunningham J, et al. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol Ther. 2001; 4: 324-30
|
|
|
|
|
|
4) Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009 Oct 21 [Epub ahead of print]
|
|
|
|
|
|
5) Azzouz M, Martin-Rendon E, Barber RD, et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci. 2002; 22: 10302-12
|
|
|
|
|
|
6) Muramatsu S, Fujimoto K, Ikeguchi K, et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther. 2002; 13: 345-54
|
|
|
|
|
|
7) Horger BA, Nishimura MC, Armanini MP, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci. 1998; 18: 4929-37
|
|
|
|
|
|
8) Gasmi M, Herzog CD, Brandon EP, et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther. 2007; 15: 62-8
|
|
|
|
|
|
9) Herzog CD, Brown L, Gammon D, et al. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery. 2009; 64: 602-12; discussion 612-3
|
|
|
|
|
|
10) Marks WJ, Jr., Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008; 7: 400-8
|
|
|
|
|
|
11) During MJ, Kaplitt MG, Stern MB, et al. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther. 2001; 12: 1589-91
|
|
|
|
|
|
12) Luo J, Kaplitt MG, Fitzsimons HL, et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science. 2002; 298: 425-9
|
|
|
|
|
|
13) Emborg ME, Carbon M, Holden JE, et al. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab. 2007; 27: 501-9
|
|
|
|
|
|
14) Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007; 369: 2097-105
|
|
|
|
|
|
15) Feigin A, Kaplitt MG, Tang C, et al. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A. 2007; 104: 19559-64
|
|
|
|
|
|
16) Montgomery EB, Jr. Basal ganglia pathophysiology in Parkinson's disease. Ann Neurol. 2009; 65: 618; author reply 618-9
|
|
|
|
|
|
17) Obeso JA, Rodriguez-Oroz MC, Benitez-Temino B, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord. 2008; 23 Suppl 3: S548-59
|
|
|
|
|
|
18) 橋本隆男. ニューロン活動からみた基底核機能. In: 柳澤信夫, 篠原幸人, 岩田 誠, 他編. Annual Review 神経 2009. 東京: 中外医学社; 2009. p. 176-83
|
|
|
|
|
|
19) Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003; 80: 148-58
|
|
|
|
|
|
20) Nam CH, Rabbitts, TH. The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. Mol Ther. 2006; 13: 15-25
|
|
|
|
|
|
21) Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006; 13: 1031-49
|
|
|
|
|
|
22) Woods NB, Bottero V, Schmidt M, et al. Gene therapy: therapeutic gene causing lymphoma. Nature. 2006; 440: 1123
|
|
|
|
|
|
23) Bankiewicz KS, Forsayeth J, Eberling JL, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther. 2006; 14: 564-70
|
|
|
|
|
|
24) Frank KM, Hogarth DK, Miller JL, et al. Investigation of the cause of death in a gene-therapy trial. N Engl J Med. 2009; 361: 161-9
|
|
|
|
|
|
25) Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007; 317: 477
|
|
|
|
|
|
26) Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009; 137: 1005-17
|
|
|
|
|
|
27) Ito T, Yamamoto S, Hayashi T, et al. A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralising antibodies. Ann Clin Biochem. In press
|
|
|
|
|
|
28) Azzouz M, Kingsman SM, Mazarakis ND. Lentiviral vectors for treating and modeling human CNS disorders. J Gene Med. 2004; 6: 951-62
|
|
|
|
|
|
29) Muramatsu S, Tsukada H, Nakano I, et al. Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors. Expert Opin Biol Ther. 2005; 5: 663-71
|
|
|
|
|
|
30) Sethi K. Levodopa unresponsive symptoms in Parkinson disease. Mov Disord. 2008; 23 Suppl 3: S521-33
|
|
|
|
|
|
31) Li XG, Okada T, Kodera M, et al. Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease. Mol Ther. 2006; 13: 160-6
|
|
|
|
|